Ligobesy

Liraglutide, the active ingredient in Ligobesy, is a GLP‑1 receptor agonist presented as a sterile solution for subcutaneous use. It is indicated for the management of type 2 diabetes mellitus and for weight management in adults with obesity, administered under medical supervision.

GNH USA supplies Ligobesy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable cold‑chain logistics for biologic products.

Ligobesy is a GLP‑1 receptor agonist that acts on the incretin pathway to improve glycaemic control and aid weight reduction.

Type 2 diabetes mellitus: improves blood glucose levels and reduces HbA1c when used with diet and exercise. Obesity / weight management: promotes satiety and helps achieve clinically meaningful weight loss in adults with a body‑mass index ≥30 kg/m² or ≥27 kg/m² with comorbidities.

Liraglutide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Nausea - Vomiting - Diarrhoea - Constipation - Headache - Decreased appetite

Serious or Rare Side Effects: - Acute pancreatitis - Gallbladder disease (cholelithiasis, cholecystitis) - Severe hypoglycaemia (especially with insulin or sulfonylureas) - Thyroid C‑cell tumours (observed in rodent studies) - Anaphylactic reactions or severe allergic responses

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor blood glucose: adjust concomitant antidiabetic agents to avoid hypoglycaemia. Assess renal function: use with caution in patients with impaired renal function. Screen for pancreatitis: discontinue if signs of acute pancreatitis develop. Review thyroid history: avoid in individuals with personal or family history of medullary thyroid carcinoma or MEN 2. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Medications known to cause pancreatitis: may potentiate pancreatic inflammation.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation parameters. - Oral contraceptives: potential changes in absorption, observe efficacy. - Diuretics: monitor renal function and electrolytes during combined therapy.